Caris Life Sciences’ Molecular Intelligence Platform Identifies Patients with MSI-High (or Mismatch Repair Deficient) Solid Tumors More Likely to Respond to Immunotherapy
Results Published in Science Demonstrate Molecular Profile of Tumor Cells Rather than Tumor Origin Can Drive Therapeutic Strategy IRVING, Texas, June 8, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today highlighted an article published in Science containing data on microsatellite instability (MSI) status and mismatch repair (MMR)-deficient tumors on a
Read more →